223 related articles for article (PubMed ID: 14581343)
1. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Minna JD; McConnell J; Frenkel EP; Gazdar AF
Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features.
Sathyanarayana UG; Padar A; Suzuki M; Maruyama R; Shigematsu H; Hsieh JT; Frenkel EP; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6395-400. PubMed ID: 14695140
[TBL] [Abstract][Full Text] [Related]
4. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Kang GH; Lee S; Lee HJ; Hwang KS
J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
[TBL] [Abstract][Full Text] [Related]
5. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
7. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
8. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
9. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
[TBL] [Abstract][Full Text] [Related]
10. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
11. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
14. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Harada K; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Vakar-Lopez F; Minna JD; Sagalowsky A; Czerniak B; Gazdar AF
Cancer Res; 2001 Dec; 61(24):8659-63. PubMed ID: 11751381
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
17. Age-related DNA methylation changes in normal human prostate tissues.
Kwabi-Addo B; Chung W; Shen L; Ittmann M; Wheeler T; Jelinek J; Issa JP
Clin Cancer Res; 2007 Jul; 13(13):3796-802. PubMed ID: 17606710
[TBL] [Abstract][Full Text] [Related]
18. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
19. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
Lewis CM; Cler LR; Bu DW; Zöchbauer-Müller S; Milchgrub S; Naftalis EZ; Leitch AM; Minna JD; Euhus DM
Clin Cancer Res; 2005 Jan; 11(1):166-72. PubMed ID: 15671542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
